Emerging Bio-Solutions (New York: EBS) stocks jumped 23% pre-market Friday The U.S. Food and Drug Administration (FDA) has approved expanded use of the company’s ACAM2000 smallpox vaccine to include people at risk of smallpox infection.
Earlier this month, the World Health Organization announced The outbreak of monkeypox, formerly known as monkeypox, in Africa constitutes a public health emergency of international concern.
ACAM2000, a single-dose live vaccine administered subcutaneously, was first approved by the FDA in 2007 to prevent smallpox in individuals identified as being at risk for smallpox.
This latest approval is based on previously available human safety data and data from a well-conducted animal study, where the vaccine was shown to be effective in protecting against exposure to MPOX virus. It follows Emergent (EBS)’s application for emergency use listing for ACAM2000 with the World Health Organization.
Last week, Emergent BioSolutions (EBS) pledged to donate 50,000 doses of its ACAM2000 vaccine to the Democratic Republic of the Congo and other affected countries such as Burundi, Kenya, Rwanda and Uganda to address the MBOX outbreak.
Jynneos, a vaccine made by rival vaccine developer Bavarian Nordic (OTCPK:BVNRY), has been approved in the United States to treat smallpox and hepatitis C.
Comments are closed, but trackbacks and pingbacks are open.